CN Patent

CN121399106A — 制备hiv衣壳抑制剂的方法

Assigned to Gilead Sciences Inc · Expires 2026-01-23 · 0y expired

What this patent protects

本公开整体上涉及用于制备可用于预防或治疗逆转录病毒科病毒感染，包括由人类免疫缺陷病毒（HIV）导致的感染的化合物的方法。

USPTO Abstract

本公开整体上涉及用于制备可用于预防或治疗逆转录病毒科病毒感染，包括由人类免疫缺陷病毒（HIV）导致的感染的化合物的方法。

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: CN121399106A
Jurisdiction: CN
Classification: —
Expires: 2026-01-23
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.